SequelSEC

AEON Biopharma, Inc. AEON

Pharmaceutical Preparations · CIK 0001837607 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$12.80M
Fiscal year ended 2025-12-31
Free cash flow
-$17.31M
Fiscal year ended 2025-12-31

AEON Biopharma, Inc. (AEON) reported net income of -$39.22M for the fiscal year ended 2025-12-31. This page shows 4 annual periods of income statement, balance sheet and cash flow figures normalized from AEON Biopharma, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

AEON Biopharma, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312022-12-312021-12-31
RevenueUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailable
Operating income-$12.80M$72.98M-$48.43M-$1.94M
Net income-$39.22M$42.00M-$52.56M$8.20M
Research & development$4.09M$14.18M$34.75MUnavailable
Weighted-average diluted sharesshares 9.92MUnavailableshares 138.85MUnavailable
Pretax income-$39.22M$42.00M-$52.56M$8.20M
Income tax expense$0$0$0Unavailable
Diluted EPS$-3.95$72.93$-0.38Unavailable
Selling, general & administrative$12.21M$13.64M$13.68MUnavailable
General & administrativeUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailable

Balance

AEON Biopharma, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312022-12-312021-12-31
Cash & equivalents$3.01M$13.00K$9.75M$497.41K
Total assets$5.56M$3.14M$10.78M$276.95M
Current assets$3.40M$1.59M$9.84M$835.22K
Total liabilities$60.59M$31.71M$143.24M$17.88M
Current liabilities$6.90M$14.15M$82.57M$834.58K
Total equity incl. NCI-$55.03M-$28.57M-$270.41M-$223.82M
Temporary (mezzanine) equityUnavailableUnavailable$137.95M$276.00M
InventoryUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailable
Accounts payable$942.00K$5.91M$7.80MUnavailable

Cash flow

AEON Biopharma, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312022-12-312021-12-31
Operating cash flow-$17.31M-$20.29M-$35.58M-$1.49M
Capital expenditures$4.00KUnavailable$306.00KUnavailable
Investing cash flow-$4.00KUnavailable-$306.00K-$276.00M
Financing cash flow$20.30M$15.15M$40.51M$277.99M
Net change in cash$2.99M-$5.14M$4.62M$497.41K
Stock-based compensation$5.32M$6.25M$5.89MUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$78.00K$97.00K$68.00KUnavailable

Derived

AEON Biopharma, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312022-12-312021-12-31
Free cash flow-$17.31MUnavailable-$35.89MUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailable
Current ratio0.49x0.11x0.12x1.00x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailable0.0%UnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open AEON in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-12View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-30View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2021-12-31

Difference 206894145 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.